MirXes is a biotechnology company that develops RNA technology for diagnostic applications. The company focuses on creating precision diagnostic tools, particularly in the field of preventive and personalized healthcare.

MirXes

MiRXES USA

M Diagnostics

Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum.

We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide.

Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. 

We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.

MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.

Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases.

We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.

Venturecraft Group

Rock Springs Capital

CR-CP Life Science Fund

EDBI

CCBI Tech Venture

Charoen Pokphand Group

Keytone Ventures

CCB International

CDG Capital

New Horizons Venture Capital

The Agency for Science, Technology and Research

Mitsui & Co

China Fellow Partners

NHH Ventures

Mirxes

#Mirxes is thrilled that our Co-Founder and CEO Dr Zhou Lihan has been appointed a member of the inaugural Future Economy Advisory Panel (FEAP), chaired by Deputy Prime Minister Heng Swee Keat. We are a small but ambitious company, and we believe our commitment to innovation can contribute significantly to shaping Singapore's precision medicine landscape 💪

#preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research

As a Singapore-headquartered biotechnology company, #Mirxes recognised early on that expanding into larger markets is essential for growth and scale. China, with its vast population and increasing healthcare demands, presented a prime opportunity.

At last Friday’s (16 Aug 2024) Singapore-China Business Forum, organised by Singapore Chinese Chamber of Commerce & Industry, our CEO and Co-Founder Dr Lihan Zhou discussed Mirxes' strategic approach to leveraging the dual engines of Singapore and China to accelerate biotechnology innovation, product development and commercialisation.

Beyond China, Dr Zhou highlighted Singapore's role as a development hub for ASEAN and global market access, particularly for innovative sectors like biotechnology. He emphasised the potential for collaboration between Chinese and Singapore companies to leverage Singapore's established networks in ASEAN. For example, by further developing their products/ideas with Singapore partners, Chinese companies with suitable offerings can more effectively expand their reach and market share within the ASEAN region.

#preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research #China #regionalisation #collaboration

#Mirxes is grateful that #MINDS had invited us to celebrate National Day with their clients.

The celebration was filled with warmth, laughter and positivity, creating an uplifting mood for everyone. While interacting with individuals with special needs was a new experience for many of us, we were immediately met with genuine smiles, infectious enthusiasm and a sincere desire to connect. We thoroughly enjoyed our time together and certainly hope to be back soon.

Thank you, MINDS clients, for reminding us the kindness, goodness and simple joy in this world ☺️

#NationalDay #CSR #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research

Happy 59th birthday, Singapore 🇸🇬 🇸🇬 🇸🇬 

Singapore may not be the perfect match for a fast growing biotechnology company. A small domestic market makes scaling up more challenging, and a capital market less accustomed to higher risk R&D-intensive ventures. 

Yet #Mirxes has flourished over the past 10 years, growing from an A*STAR spin-off to a leading RNA technology player with proprietary intellectual property and commercialised offerings. Singapore has walked the journey with us, providing exceptional talent pool, supportive policies, and conducive business climate to counter the inherent hurdles.

We are proud to call Singapore home, and we will continue to innovate and manufacture at home for the world.

#NationalDay #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research

Exciting times ahead for the Singapore Vandas! With our First Lady as its Patron, netball in Singapore will undoubtedly be elevated to new heights.

Netball is already a popular sport among many Singaporeans, especially our schoolgirls. #Mirxes is incredibly proud to support Netball Singapore in their mission to make this fantastic sport more accessible and popular, just like how Mirxes is striving to make cancer early detection more accessible and common.

It’s a pity netball did not make the cut for Paris Olympics this year. We certainly hope to see netball on the Olympic stage with Singapore proudly represented in the future 💪

#NetballSingapore #NewPatron #SportsDevelopment #Singapore

Happy #RNAday! On 1 August, we celebrate the latest discoveries and advancements in RNA research. To reaffirms our commitment in empowering spatial transcriptomics research, #Mirxes is excited to announce our sponsorship of SingHealth Immunopathology Workshop 2024’s Poster Prize. 
 
Calling all pathologists and researchers in pathology! Submit your poster now and stand a chance to win a complimentary 1cm x 1cm Stereo-seq chip full service* from us. 
 
*Terms and conditions apply

Find out more at https://lnkd.in/gwC_Cr2H
 
#preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research #earlydetection #Genomics #spatial #NGS #sequencing

#Mirxes is excited and honoured to announce a groundbreaking partnership with Universiti Kebangsaan Malaysia (UKM) to advance colorectal cancer early detection in Malaysia!

The #MOU signed today, witnessed by Malaysian Prime Minister Anwar Ibrahim and Science, Technology and Innovation Minister Chang Lih Kang, marks a significant milestone for Mirxes as we expand our presence in Malaysia.

By combining UKM’s world-class cancer and molecular biology research with our proprietary #miRNA technology, and leveraging archived biospecimens from Medical Molecular Biology Institute (UMBI) and The Malaysian Cohort Biobank, Southeast Asia's largest biobank, we will identify crucial #biomarkers that are needed for an accurate and sensitive blood-based colorectal cancer early detection test.

And it does not stop here. This partnership also paves the way for the potential development and commercialisation of a wider range of made-in-Malaysia blood-based cancer early detection tests such as those for stomach and lung cancers.

“A strong and like-minded local partner like UKM is crucial for the deployment of our proprietary miRNA technology and commercialisation of novel cancer screening tests,” said Dr Lihan Zhou, Co-Founder and CEO of Mirxes. “Together, we’re committed to co-developing and making accessible our portfolio of blood-based cancer early detection tests in Malaysia.”

#preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research #earlydetection #partnership #collaboration #molecularbiology #colorectalcancer

#Mirxes #Genomics team introduced our new single-cell Whole Genome Sequencing (scWGS) service at the Single Cell Congress: Asia 2024 on 11-12 July, and enjoyed engaging and interacting with speakers and attendees.
 
Discover single cell clarity with Mirxes today: https://lnkd.in/gDEzKA4M

#preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research #earlydetection #scWGS

A road less travelled to success
 
Successful listing on the Hong Kong Stock Exchange (HKEX) would be a significant milestone for #Mirxes, but it's not the finish line. We view it as a validation of the hard work by our team, and the trust placed in us by our investors and partners. However, the journey continues. We remain dedicated to overcoming the challenges that lie ahead, and flying the Singapore flag high in the global biotech scene. 
 
Excerpts from the Tech-In-Asia article:
 
1. CEO Lihan Zhou points out that the biotech ecosystems in the US, including those in Boston and San Francisco, took “four to five decades to get to where they are [today].” So, what Singapore has achieved in this time frame, compared to the US, is “not bad.” As of 2022, just three out of 52 biotech firms in Singapore were in the commercialization stage. Meanwhile, 14 companies were in the clinical phase, and the vast majority of them were in preclinical stages.

2. Zhou challenges the perception of an IPO as a hallmark for success: “Frankly, at year eight or nine [from our year of founding], going for IPO to raise money to develop and commercialize my product is late” compared to US peers, who typically get listed within their first six years, Zhou notes. For biotech firms, listing on the public markets is “just a fundraising event” to bankroll further development, including clinical trials. The CEO adds that a majority of biotech firms listed on the Nasdaq or in Hong Kong are not revenue-generating – much less profitable – and don’t pay dividends. That’s a “drastic contrast” to how most Asian retail investors perceive IPO-stage companies.

3. Compared to its peers in the US, which are burning “US$200 million to US$250 million a year” to do clinical work, Mirxes is more cost-efficient, recording “about US$50 million” in operational expenses to do the same, while scaling its commercial products and bringing in revenue, the CEO notes. In 2023, Mirxes reported an operating loss of US$70.4 million, a 22% increase year on year, as revenue grew 36% to US$24.2 million. At that annual revenue, Mirxes has exceeded the US$10 million threshold that Zhou considers to be a benchmark for a commercial biotech firm displaying both traction and scale. That said, it “would take 10 to 15 years” to get from the US$10 million threshold to achieving profitability, even in the US, he notes. “Profitability for biotech companies is a complex question.”

#preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research #earlydetection

Read more at: https://lnkd.in/gWGWWbuP

#Mirxes has launched our new research service - Single-cell Whole Genome Sequencing (scWGS). With scWGS, you can confidently capture somatic mosaicism at the single-cell level and unravel cell lineage. 
 
Our scWGS service offers:
- Exceptional Whole Genome Amplification performance (high genome coverage, low amplification error and reduced artifacts)
- End-to-end service (Sample preparation, Sequencing and Bioinformatics analysis)
- Expert Bioinformatics support (CNV, SNV, indel analyses etc)
 
Explore our cutting-edge scWGS service today: https://lnkd.in/gDEzKA4M
 
#preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research #Genomics #singlecell #sequencing

Metric
Company Name	MirXes
Symbol
MSH ID	COM:MIRXES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	SG
Stage
Employee Count	251
Website	mirxes.com
LinkedIn	mirxes
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

MIRX

COM:MIRXES

MirXes

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue